Manufacturer
Sun Pharmaceutical Industries Ltd.
Contents
Octreotide acetate
Indication
Acromegaly/ Variceal haemorrhage in patients with cirrhosis/ Prophylaxis of complications following pancreatic surgery/ Secretory neoplasms/ HIV-associated diarrhoea
Instruction
Administer via IM/ IV/ S/C
Drug interaction
Dosage adjustment of concurrent therapy may be necessary with calcium channel blockers, oral hypoglycaemics, β-blockers, diuretics. May increase concentration of bromocriptine.
Potentially Fatal: Requirements of insulin may be reduced requiring careful blood-glucose monitoring. Reduction in ciclosporin bioavailability and efficacy.
Octride Injection 50mcg/ml